NDUFB9
ENSG00000147684
Target class
Enzyme
Chromosome
8
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFB9
- Gene name
- NADH:ubiquinone oxidoreductase subunit B9
- Gene symbol
- NDUFB9
- Protein name
- NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 (Complex I-B22) (CI-B22) (LYR motif-containing protein 3) (NADH-ubiquinone oxidoreductase B22 subunit)
- B22
- UQOR22
- LYRM3
- Gene biotype
- Protein coding
- Gene family
- LYR motif containing|NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 299.49
- Tissue specificity (Gini)
- 0.182
- Tissue specificity (tau)
- 0.668
- KEGG gene identifiers
- hsa:4715
- Protein interaction confidence
- 0.927983
- Protein interaction partners
- 120
- R-HSA-611105
- R-HSA-6799198
- End position
- 124580648
- Start position
- 124539101
- Chromosome
- 8
- Strand
- Forward
- Mitochondrion inner membrane
- Peripheral membrane protein
- Matrix side .
- Mitochondria
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.667735
- Expression inequality (Gini)
- 0.181751
Expression in transcripts per million
- Muscle - Skeletal
- 299.49
- Heart - Left Ventricle
- 188.24
- Brain - Frontal Cortex (BA9)
- 161.81
- Testis
- 159.19
- Heart - Atrial Appendage
- 158.02
Expression in transcripts per million
- Muscle - Skeletal299.49
- Heart - Left Ventricle188.24
- Brain - Frontal Cortex (BA9)161.81
- Testis159.19
- Heart - Atrial Appendage158.02
- Brain - Anterior cingulate cortex (BA24)147.01
- Brain - Substantia nigra146.86
- Kidney - Medulla138
- Brain - Cortex133.08
- Brain - Amygdala129.59
- Brain - Nucleus accumbens (basal ganglia)121.44
- Brain - Cerebellar Hemisphere121.03
- Brain - Hypothalamus111.23
- Colon - Sigmoid111.03
- Esophagus - Muscularis109.03
- Brain - Cerebellum109.02
- Thyroid108.11
- Colon - Transverse107.8
- Esophagus - Gastroesophageal Junction106.59
- Artery - Tibial103.38
- Brain - Hippocampus102.07
- Brain - Spinal cord (cervical c-1)101.96
- Brain - Caudate (basal ganglia)101.19
- Stomach99.56
- Brain - Putamen (basal ganglia)99.55
And 29 more, listed on the interactive page.
- GO:0006120
- GO:0007605
- GO:0005739
- GO:0005743
- GO:0045271
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor